Acticor Biotech annonce la fin du recrutement de GARDEN, son étude clinique d’efficacité dans le Syndrome de Détresse Respiratoire Aigüe lié à la COVID-19

Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase of ischemic stroke and thrombotic diseases, today announces the completion of recruitment in GARDEN, its phase 2 clinical study on the use of glenzocimab, a novel humanized monoclonal antibody fragment, in patients with COVID-19- induced Acute Respiratory Distress Syndrome (ARDS). [...]